DrugPatentWatch Database Preview
Details for Patent: 6,376,515
Email this page to a colleague
See Plans and PricingWhich drugs does patent 6,376,515 protect, and when does it expire?
Patent 6,376,515 protects BEVYXXA and is included in one NDA.
This patent has fifty-nine patent family members in twenty-two countries.
Summary for Patent: 6,376,515
| Title: | Benzamides and related inhibitors of factor Xa |
| Abstract: | Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| Inventor(s): | Zhu; Bing-Yan (Belmont, CA), Zhang; Penglie (Foster City, CA), Wang; Lingyan (Chatham, NJ), Huang; Wenrong (Cupertino, CA), Goldman; Erick A. (San Francisco, CA), Li; Wenhao (South San Francisco, CA), Zuckett; Jingmei (Glendale, AZ), Song; Yonghong (Foster City, CA), Scarborough; Robert M. (Half Moon Bay, CA) |
| Assignee: | COR Therapeutics, Inc. (South San Francisco, CA) |
| Application Number: | 09/794,225 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Device; |
Drugs Protected by US Patent 6,376,515
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS | Start Trial | ||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) | Start Trial | ||
| Portola Pharms Inc | BEVYXXA | betrixaban | CAPSULE;ORAL | 208383-001 | Jun 23, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | PROPHYLAXIS OF PULMONARY EMBOLISM | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,376,515
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 311366 | Start Trial | |||
| Austria | 412629 | Start Trial | |||
| Australia | 4535301 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
